Result of AGM

RNS Number : 9010R
Concepta PLC
02 July 2020
 

Concepta PLC

("Concepta" or the "Company")

 

Result of AGM

 

Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of myLotus®, the UK's most accurate home-use fertility tracking and pregnancy self-testing system, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

Details of voting are provided below:

 

Resolution

For

Against

Resolution 1

107,315,949

86,504

Resolution 2

107,320,669

63,504

Resolution 3

106,115,669

1,266,784

Resolution 4

106,120,669

1,286,504

Resolution 5

106,070,949

1,336,504

Resolution 6

106,070,949

1,336,504

Resolution 7

106,120,949

1,286,504

Resolution 8

105,846,568

1,470,127

Resolution 9

104,660,762

2,655,653

 

 

Concepta plc

www.conceptaplc.com

P enny McCormick , Chief Executive Officer

via Walbrook PR

Maddy Kennedy, Chief Financial Officer




SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin




Novum Securities (Broker)

Tel: +44 (0)20 7399 9400

Colin Rowbury




Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com

Paul McManus

Mob: +44(0)7980 541 893

 

 

About Concepta PLC ( www.conceptaplc.com )

 

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

 

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus®   is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

 

The Company has received CE-mark certification for myLotus®   and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.

 

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGZLLFBBDLLBBF
UK 100

Latest directors dealings